Program
+ EXPAND all sections 
To expand/collapse individual sections, click the section title or grey arrow.
Sunday, 10 October
Visit the registration desk to check in on Sunday, which allows you to jump-start your networking opportunities at the Welcome Drinks Reception in the Benjamin Britten Lounge on the 3rd Floor.
By registering early, you'll be able to collect your name badge, program, and handbag materials and avoid long lines on Monday morning.
You are invited to attend the opening reception of the 18th Annual BioPartnering Europe. After checking in at Registration, head to the 3rd Floor for drinks and delicious hors d'œuvres.
Monday, 11 October
Join us for a refreshing continental breakfast of fresh orange juice, muffins and breakfast pastries. Freshly brewed coffee, decaffeinated coffee, breakfast and herbal teas will also be available.
Title: Welcome to the 18th Annual BioPartnering Europe!
On behalf of TVG, our sponsors and supporters, Dr. Robert L. Kilpatrick will welcome delegates to London, where BPE continues as the original European-based international partnering event. Founded in 1993, BPE has anticipated and satisfied a growing need for life science companies to create valuable global partnerships.
As Europe’s longest-running life science partnering meeting, BPE has consistently demonstrated an ability to reinvent itself. BPE continues to be supported by a “Who’s Who” of sponsors and organizations from around the world, including members of the Regional Affiliates Program. |
|
Thank you for helping us to keep BPE at the forefront of life science business partnering. We wish you a fruitful and enjoyable time.
Speaker:
Dr. Robert Lee Kilpatrick, Partner, TVG
Title: Building Creative Partnerships from Molecule to Market
The benefits of partnerships in drug discovery, development, and distribution are well established and accepted. But today, there is a wealth of opportunity to go beyond traditional partnerships (often between pharmaceutical and biotech companies) to broaden access to the world of scientific innovation.
AstraZeneca has led the way in forging creative, non-traditional agreements that bring together unexpected partners in mutually beneficial, value-enhancing ways. In this speech, Ekblom will discuss how the industry might rethink partnerships to bring not only pharma and biotech together, but also academia, government, NGOs, venture capital and thought leaders to the table. He will also discuss the benefits of crossing geographic lines to form global partnerships that draw on the strengths of different cultures and populations. Ekblom will use recent examples of AstraZeneca’s creative partnerships to showcase the advantages, nuances, and best practices of this 360° approach to innovative collaboration.
Speaker:
Dr. Anders Ekblom, Executive Vice President, Global Medicines Development, AstraZeneca
Title: Today's Merck: Broadening our Horizons
Merck and Schering-Plough announced the finalization of their merger in November 2009 and today have a fully integrated and robust new pipeline. Dr. David Nicholson, who heads Merck's Worldwide Licensing and External Research team, has spent his career in global pharmaceutical research. He will speak about Today's Merck and its heightened focus on novel, cutting-edge partnerships -- both inlicensing and outlicensing. He will also share the latest information on Merck's broader global reach into new markets, our great hopes for RNA therapeutics and follow-on biologics, and the intense worldwide search for biotech and academic partners who will join Merck in facing these new frontiers.
Speaker:
Dr. David Nicholson, Senior Vice President, Worldwide Licensing and Knowledge Management, Merck & Co., Inc.
| All meetings scheduled through biopartnering.com will be held at the numbered booths and lettered tables in the Fleming & Whittle Rooms (3rd Floor). Please visit the onsite Meeting & Message Desks for assistance. |
 |
Title: Deal or No Deal? Maintaining Your Options
Make a deal, raise more cash, go public? Every biotech board room has heard intense debate on what is the best strategy to meet today's challenging and changing life science business environment.
How can we keep going long enough to get the best terms?
How can we lock in a deal on one product that won't reduce the value of our pipeline for other partners?
Is an IPO worth the risk?
Overall, the biotech industry has raised $2.1 billion in 238 deals through the end of June 2010, according to the National Venture Capital Association - but what will those deals cost the companies long-term?
While there have been some successes in the IPO market, such as Ironwood Pharmaceuticals which raised $203 million in its initial public offering at a $1.4 billion valuation, the IPO market continues to reflect uncertainty in the stock market with investors remaining gun-shy when it comes to backing companies with a lot of development risk and no marketed products.
Is the IPO window open wide enough to be a viable financial strategy?
This panel brings together biotech leaders and venture capitalists who have successfully made deals and/or raised money in an environment where old models no longer work and new models have yet to emerge.
Panelists will discuss how to maintain a position of strength - making deals that are advantageous to the company and its pipeline in the long-term, while alleviating short-term cash pressure.
Refresh yourself with a delicious hot lunch buffet of beef chuck, thyme and roasted red onions in a balsamic glaze sauce; mash with rosemary and garlic oil; seared tuna niçoise; Mediterranean vegetable and smoked mozzarella quiche; as well as a variety of mouthwatering salads. Choose from several tantalizing desserts such as an apple, sultana and cinnamon puff slice, an almond and blackberry roulade, or fresh fruit.
Title: The View From the Buy-Side: Lessons and trends in biopharma deal-making
Once you’ve funded your biopharma company, how do you build something of value and leverage your asset by tapping into outside resources? We will take the ‘buy-side’ perspective as we examine the critical elements of a licensing dossier, the due diligence process, the benefits of different partnering vehicles and the realistic valuation of licensing opportunities. In so doing, we will draw upon recent trends, benchmarking examples and case studies in biopharma deal-making.
Deloitte Recap LLC (formerly Recombinant Capital, Inc.), has been providing analysis and insights partnering for over 20 years as a trusted advisor to the biotech industry. Deloitte Recap LLC has advised hundreds of biotech companies and assisted on more than $12 billion of announced new partnering deals.
Speaker:
Dr. Chris Britten, Director, London, Corporate Finance Advisory, Deloitte LLP
Speaker:
Mr. Michael S Johnson, Practice Leader, Deloitte Recap LLC
Tuesday, 12 October
Join us for a refreshing continental breakfast of fresh orange juice, muffins and breakfast pastries. Freshly brewed coffee, decaffeinated coffee, breakfast and herbal teas will also be available.
Title: The Coming Tsunami of Regenerative Medicine and the Advent of Stem Cell-Based Therapies
The practice of medicine will be forever changed when specific tissue/organs can be repaired or replaced either by direct cell therapeutics or by “agent molecules” (biological or chemical compounds) that trigger endogenous processes in the body. The burgeoning field of Regenerative Medicine, frequently but incompletely exemplified by Stem Cell-based treatment, is the subject of our panel from US and non-US pharmas and biotech. Increasing amounts of discovery and clinical research funding and efforts are taking place in this new field, which is also the source of new research tools that are being deployed to find/perfect therapeutics for use in many discovery categories. The panelists will discuss how their companies view Regenerative Medicine overall, and what is being done internally or with partnerships to progress their pipelines.
Chair: Mr. William J Kridel, Managing Director, Ferghana Partners Group
Speaker: Dr. Robert J Hariri, CEO, Celgene Cellular Therapeutics
| All meetings scheduled through biopartnering.com will be held at the numbered booths and lettered tables in the Fleming & Whittle Rooms (3rd Floor). Please visit the onsite Meeting & Message Desks for assistance. |
|
In this presentation, the speaker will highlight the strengths of their company, which may include a company overview, an outline of products on the market, and information about alliances, existing or sought.
In this presentation, the speaker will highlight the strengths of their company, which may include a company overview, an outline of products on the market, and information about alliances, existing or sought.
In this presentation, the speaker will highlight the strengths of their company, which may include a company overview, an outline of products on the market, and information about alliances, existing or sought.
Speaker:
Dr. Shelagh Wilson, Vice President, Business Development Rare Diseases, GlaxoSmithKline
In this presentation, the speaker will highlight the strengths of their company, which may include a company overview, an outline of products on the market, and information about alliances, existing or sought.
Speaker:
Dr. Hans Christinger, Global Alliance Director, Roche
In this presentation, the speaker will highlight the strengths of their company, which may include a company overview, an outline of products on the market, and information about alliances, existing or sought.
Continue your networking over a delicious lunch of chicken, lemon and ginger with mange tout; parsley new potatoes; salmon wellington; leek, sun-blushed tomato and ricotta cannelloni; and three salad options that are sure to satisfy your hunger and prepare you for a successful afternoon of partnering. Complete the meal with a peach melba bakewell tart, a two-tone chocolate mousse, and fresh fruit.
Title: Bristol-Myers Squibb - The Next Generation Biopharma Company
In this presentation, the speaker will highlight the strengths of their company, which may include a company overview, an outline of products on the market, and information about alliances, existing or sought.
Speaker:
Dr. Lubor Gaal, Executive Director, Strategic Transactions Group, Bristol-Myers Squibb
In these dedicated presentations, biotechnology companies from around the world have the opportunity to briefly introduce their company, highlight key technologies, alliances, and where they stand with product & clinical developments.
In these dedicated presentations, biotechnology companies from around the world have the opportunity to briefly introduce their company, highlight key technologies, alliances, and where they stand with product & clinical developments.
Title: Partnering with Novartis
| What Novartis can offer as a partner in an increasingly complex, regulated and cost conscious HC environment. |
 |
Speaker: Dr. Axel Maibuecher, Head of Search and Evaluation for Integrated Hospital Care, Global BD&L, Novartis Pharma AG
In this presentation, the speaker will highlight the strengths of their company, which may include a company overview, an outline of products on the market, and information about alliances, existing or sought.
Speaker:
Mr. David Brady, Vice President, Business Development, Takeda Pharmaceuticals Europe
In this presentation, the speaker will highlight the strengths of their company, which may include a company overview, an outline of products on the market, and information about alliances, existing or sought.
In this presentation, the speaker will highlight the strengths of their company, which may include a company overview, an outline of products on the market, and information about alliances, existing or sought.
Speaker:
Dr. Barbara Yanni, Vice President & Chief Licensing Officer, Merck & Co., Inc.
Title: Autumn Market Report
A complete review of the Life and Health Sciences sector across Europe, including comparisons with the US. Metrics will be presented and leading members of the professional investment community will provide commentary and predictions for the coming six months. This event, and the drinks reception which follows, is being offered to invited guests at no charge.
Chair: Dr. Chris Britten, Director, London, Corporate Finance Advisory, Deloitte LLP
| An opportunity to say goodbye to fellow delegates and begin planning for the 19th Annual BioPartnering Europe. |
|
